Europe L-Carnosine Market Trends, Future Outlook, COVID-19 Impact Analysis, Forecast 2022-2028

Europe L-carnosine market is estimated to grow at a CAGR of around 4.3% during the forecast period. The market is driven by increasing diabetes, eye disorders (cataracts), and kidney-related disorders. There is a growing demand for L-carnosine for the prevention and treatment of complications associated with diabetes such as nerve damage, and eye disorders (cataracts). Therefore, the increasing prevalence of diabetes is one of the primary factors which is contributing to the growth of the market. According to IDF Europe, in 2018, more than 58 million diabetic people were living in Europe; this number is expected to reach 66.7 million by 2045. This trend suggests that the demand for L-carnosine in Europe will increase significantly in the near future.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/europe-l-carnosine-market

Europe L-carnosine market is segmented on the basis of application and geography. Based on the application, the market is segmented into autism, diabetes support, skin support, CVD support, joint support, and others. Others segment include digestion support, Parkinson's disease, and Alzheimer's disease. In 2019, the skin support segment is projected to contribute a significant share to the global market.

Moreover, the report covers the country-level analysis of the Europe L-carnosine market. The economies covered in the report studied include UK, Germany, Italy, Spain, France, and the Rest of Europe. UK L-carnosine market is estimated to grow significantly during the forecast period. The growth is attributed to the increasing incidence and prevalence rate of chronic diseases, such as CVDs (cardiovascular diseases) and diabetes. The prevalence of diabetes has changed significantly in the UK. It has increased from a year on year growth of 2.9% to 7.6% among men between the period 1994-2016, and 1.9% to 2.6% among women in the same period.

L-carnosine market players are making efforts to develop L-carnosine products for various purposes such as managing aging and cardiovascular health & cellular protection. Bachem AG is a Switzerland-based company offering more than 5,500 different biologically active peptides, amino acid derivatives, and biochemicals through its online portal. It has a global reach with the subsidiaries in the US, UK, and Japan. Moreover, the company has distributors network in Austria, Belgium, Brazil, Canada, France, Germany, India, Italy, Luxembourg, the Netherlands, Spain, and Taiwan. The company offers L-carnosine in a pack size of 5 gm and 25 gm. The list price of 5 gm L-carnosine is $194, and $826 for 25 gm packs.

Europe L-Carnosine Market- Segmentation

By Application

• Autism
• Diabetes
• Skin Support
• Cardiovascular Support
• Joint Support
• Others

A full report of Europe L-Carnosine Market is available at: https://www.omrglobal.com/industry-reports/europe-l-carnosine-market

Europe L-Carnosine Market- Segment by Region

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Company Profiles

• Bachem AG
• Cambridge Bioscience Ltd.
• Jarrow Formulas, Inc.
• Kirkman Group, Inc.
• Merck KGaA
• NOW Foods, LLC
• Quest Vitamins Ltd.
• ZeinPharma Germany GmbH

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.